Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Have chronic plaque psoriasis based on a diagnosis for at least 6 months before baseline as determined by the investigator.
Are a candidate for phototherapy and/or systemic therapy.
Have both an Static Physician Global Assessment (sPGA) score of ≥3 and a Psoriasis Area and Severity Index (PASI) score ≥12 at screening and at baseline.
Have ≥10% body surface area (BSA) involvement at screening and baseline.
If a male, agree to use a reliable method of birth control during the study.
If female, agree to use highly effective method of contraception.
You may not be if
Predominant pattern of pustular, erythrodermic, and/or guttate forms of psoriasis.
Have a history of drug-induced psoriasis.
Had a clinically significant flare of psoriasis during the 12 weeks before baseline.
Use of tanning booths for at least 4 weeks before baseline.
Concurrent or recent use of any biologic agent within the following periods prior to baseline: etanercept \<28 days; infliximab, adalimumab, certolizumab pegol, or alefacept \<60 days; golimumab \<90 days; rituximab \<12 months; secukinumab \<5 months; or any other biologic agent (e.g., ustekinumab) \<5 half lives.
Have prior use of IL-23p19 antagonists (e.g., guselkumab, tildrakizumab, risankizumab), or have any condition or contraindication as addressed in the local labeling for guselkumab that would preclude the participant from participating in this protocol.
Have previously completed or withdrawn from this study, participated in any other study with ixekizumab or guselkumab, have participated in any study investigating IL-23p19 antagonists, or have received treatment with ixekizumab.
Have previously failed to respond to an IL-17 antagonist, per investigator assessment.
Have had a live vaccination within 12 weeks of baseline.
Have a known allergy or hypersensitivity to any biologic therapy.
Have had any major surgery within 8 weeks of baseline.
Have had a serious infection, have been hospitalized, or have received intravenous antibiotics for an infection within 12 weeks of baseline.
Are women who are pregnant, or who are lactating (breast-feeding).
Clareo Health | A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis
